A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s ...
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...
Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug ...
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., ...
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...
England's National Health Services plans to offer Eli Lilly's weight-loss drugs to nearly a quarter million people as part of ...
Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug ...
The NHS plans to roll out Mounjaro, a weight-loss jab that can help users lose up to a quarter of their body weight, making it more potent than Ozempic. Anna Magee explains how to choose the best opti ...
In a phased rollout, the jabs eventually will be offered to those with a BMI of 35 or more and weight-related health problems ...
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...
Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, has been in short supply since 2022 amid skyrocketing demand. The medication is part of the blockbuster ...
NHS says a quarter of a million people will be offered tirzepatide - brand name Mounjaro - after trials showed it helped obese participants lose a fifth of their body weight ...